TANGO THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.215 USD | -2.63% |
|
+8.56% | -26.97% |
Financials (USD)
| Sales 2024 * | 31.31M | Sales 2025 * | 31.62M | Capitalization | 792M |
|---|---|---|---|---|---|
| Net income 2024 * | -140M | Net income 2025 * | -153M | EV / Sales 2024 * | 26.4 x |
| Net Debt 2024 * | 34.45M | Net cash position 2025 * | 239M | EV / Sales 2025 * | 17.5 x |
| P/E ratio 2024 * |
-5.74
x | P/E ratio 2025 * |
-5.68
x | Employees | 140 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.67% |
More Fundamentals
* Assessed data
More news
Latest transcript on Tango Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -2.63% | ||
| 1 week | +8.56% | ||
| Current month | +4.48% | ||
| 1 month | -8.37% | ||
| 3 months | -36.02% | ||
| 6 months | -13.41% | ||
| Current year | -26.97% |
1 week
6.61
7.49
1 month
6.468.38
Current year
6.4613.01
1 year
2.8813.03
3 years
2.4718.84
5 years
2.4718.84
10 years
2.4718.84
| Managers | Title | Age | Since |
|---|---|---|---|
Barbara Weber
CEO | Chief Executive Officer | 67 | 17-02-28 |
Daniella Beckman
DFI | Director of Finance/CFO | 45 | 16-09-30 |
Jannik Andersen
CTO | Chief Tech/Sci/R&D Officer | - | 18-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alexis Borisy
CHM | Chairman | 52 | 16-12-31 |
Mace Rothenberg
BRD | Director/Board Member | 67 | 21-02-28 |
Barbara Weber
CEO | Chief Executive Officer | 67 | 17-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.00% | 9 M€ | +10.33% | - | |
| 0.00% | 9 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 7.23 | -2.43% | 56 037 |
| 24-06-05 | 7.41 | +4.07% | 345,641 |
| 24-06-04 | 7.12 | +1.71% | 291,894 |
| 24-06-03 | 7 | +1.16% | 429,452 |
| 24-05-31 | 6.92 | +3.90% | 817,863 |
Delayed Quote Nasdaq, June 06, 2024 at 11:42 am EDT
More quotes
Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. Its lead program, TNG908, is an methylthioadenosine (MTA)-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor. The Company's programs also include TNG348 and TNG462. TNG348 is an allosteric inhibitor of ubiquitin-specific protease (USP1).
Calendar
2024-06-11
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
7.41
USD
Average target price
14.86
USD
Spread / Average Target
+100.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.97% | 792M | |
| +58.19% | 59.34B | |
| +43.17% | 40.24B | |
| -5.06% | 39.88B | |
| -5.56% | 28.55B | |
| +15.61% | 27.26B | |
| -21.23% | 19.23B | |
| +33.00% | 12.61B | |
| +2.80% | 12.49B | |
| +26.92% | 12.28B |
- Stock Market
- Equities
- TNGX Stock
